Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis
Quantum BioPharma signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement its Phase 2 trial of Lucid-MS in multiple sclerosis. The milestone follows FDA clearance to proceed, moving the program from regulatory clearance into formal study start-up with a CRO experienced in CNS and MS trials.
Key figures
- Drug Name
- Lucid-MS (Lucid-21-302)
- Phase Of Trial
- Phase 2
- Royalty terms
- 7% of Unbuzzd sales until payments total $250 million, then 3% in perpetuity
- Unbuzzd ownership
- 19.48%
- Ms patients worldwide
- approximately 2.8 million
- Ms market projection 2030
- $38 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.